CRYO CELL INTERNATIONAL INC(CCEL)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-05-31.

CRYO CELL INTERNATIONAL INC (CCEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CCEL at 35.0/100 on a 32-signal composite quality model, placing it at rank #2,222 of 2,856 stocks — the bottom half of the AI-ranked universe. CCEL scores in the top quartile across earnings quality (79.5). Areas of concern include revenue scale (7.1) and institutional flow (9.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 49.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRYO CELL INTERNATIONAL INC reports quarterly revenue of $7.8M, net income of $554.6K, free cash flow of $1.8M. Top institutional holders of CCEL by reported 13-F value include SFI Advisors, VANGUARD CAPITAL MANAGEMENT, MassMutual Private Wealth & , FSB, based on the most recent SEC filings. CCEL trades on the NYSE exchange and files with the SEC under CIK 862692. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRYO CELL INTERNATIONAL INC directly from SEC EDGAR.